Related references
Note: Only part of the references are listed.Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
Angela Lamarca et al.
LANCET ONCOLOGY (2021)
Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study
Liu-Fang Ye et al.
INVESTIGATIONAL NEW DRUGS (2021)
Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial
Ali Belkouz et al.
BRITISH JOURNAL OF CANCER (2020)
Systemic therapies for intrahepatic cholangiocarcinoma
Robin Kate Kelley et al.
JOURNAL OF HEPATOLOGY (2020)
A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
Ayhan Ulusakarya et al.
BMC CANCER (2020)
Medical treatment for cholangiocarcinoma
Jorge Adeva et al.
LIVER INTERNATIONAL (2019)
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study
Jean-Marc Phelip et al.
DIGESTIVE AND LIVER DISEASE (2019)
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
Jihoon Kang et al.
INVESTIGATIONAL NEW DRUGS (2018)
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
Changhoon Yoo et al.
CANCER RESEARCH AND TREATMENT (2018)
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma A Phase 2 Clinical Trial
Vaibhav Sahai et al.
JAMA ONCOLOGY (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Michiru Nishita et al.
SCIENTIFIC REPORTS (2017)
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. W. Valle et al.
ANNALS OF ONCOLOGY (2016)
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors
Caterina Vivaldi et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis
John R. Bergquist et al.
JOURNAL OF SURGICAL ONCOLOGY (2016)
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data
Lorenzo Fornaro et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
Frederic Fiteni et al.
CANCER MEDICINE (2014)
Classification, Diagnosis, and Management of Cholangiocarcinoma
Nataliya Razumilava et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma
Myoung Joo Kang et al.
ACTA ONCOLOGICA (2012)
A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score
W. Jiang et al.
ANNALS OF ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Share Paper
